Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
OncoSil Medical Ltd ( (AU:OSL) ) has issued an announcement.
OncoSil Medical Ltd announced several key developments in its quarterly report, including new distribution agreements in the GCC, Egypt, and Nordic regions, which are expected to significantly boost its presence in the global market. The company also achieved important regulatory milestones, such as the renewal of UKCA certificates and G-BA trial approval in Germany, and continued progress in clinical trials, including the first treatment in Italy and patient randomization in Australia, strengthening its position as a leader in pancreatic cancer treatment.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer. The company is involved in expanding its global presence and enhancing cancer therapeutic solutions in multiple strategic markets.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$23.03M
For detailed information about OSL stock, go to TipRanks’ Stock Analysis page.
